Quality of Life in Patients with Schizophrenia: The Impact of Socio-economic Factors and Adverse Effects of Atypical Antipsychotics Drugs
Autor(a) principal: | |
---|---|
Data de Publicação: | 2014 |
Outros Autores: | , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFRN |
Texto Completo: | https://repositorio.ufrn.br/jspui/handle/123456789/25424 http://dx.doi.org/10.1007/s11126-014-9290-x |
Resumo: | This cross-sectional study compared the effects of treatment with atypical antipsychotic drugs on quality of life (QoL) and side effects in 218 patients with schizophrenia attending the ambulatory services of psychiatric in Rio Grande do Norte, Brazil. Socio-economic variables were compared. The five-dimension EuroQoL (EQ-5D) was used to evaluate QoL, and side effects were assessed using the Udvalg for Kliniske Undersøgelser (UKU) Side Effect Rating Scale and the Simpson–Angus Scale. Data were analysed using the χ 2 test and Student’s t test, with a significance level of 5 %. Average monthly household incomes in the medication groups were 1.1–2.1 minimum wages ($339–$678). UKU Scale scores showed significant differences in side effects, mainly, clozapine, quetiapine and ziprasidone (p < 0.05). EQ-5D scores showed that all drugs except olanzapine significantly impacted mobility (p < 0.05), and proportions of individuals reporting problems in other dimensions were high: 63.6 % of clozapine users reported mobility problems, 63.7 and 56.3 % of clozapine and ziprasidone users, respectively, had difficulties with usual activities, 68.8 and 54.5 % of ziprasidone and clozapine users, respectively, experienced pain and/or discomfort, and 72.8 % of clozapine users reported anxiety and/or depression. Psychiatric, neurological, and autonomous adverse effects, as well as other side effects, were prevalent in users of atypical antipsychotic drugs, especially clozapine and ziprasidone. Olanzapine had the least side effects. QoL was impacted by side effects and economic conditions in all groups. Thus, the effects of these antipsychotic agents appear to have been masked by aggravating social and economic situations. |
id |
UFRN_46c183dcfd3e5c3f47085212bad150f5 |
---|---|
oai_identifier_str |
oai:https://repositorio.ufrn.br:123456789/25424 |
network_acronym_str |
UFRN |
network_name_str |
Repositório Institucional da UFRN |
repository_id_str |
|
spelling |
Araújo, Aurigena Antunes deDantas, Diego de AraújoNascimento, Gemma Galgani doRibeiro, Susana BarbosaChaves, Katarina MeloSilva, Vanessa de LimaAraújo Jr., Raimundo Fernandes deSouza, Dyego Leandro Bezerra deMedeiros, Caroline Addison Carvalho Xavier de2018-06-16T12:05:33Z2018-06-16T12:05:33Z2014-05-01ARAÚJO, Aurigena Antunes de et al. Quality of Life in Patients with Schizophrenia: The Impact of Socio-economic Factors and Adverse Effects of Atypical Antipsychotics Drugs. Psychiatric Quarterly, p. 357-67, 2014. Disponível em: <https://link.springer.com/article/10.1007%2Fs11126-014-9290-x>. Acesso em: 19 mar. 2018.1573-6709https://repositorio.ufrn.br/jspui/handle/123456789/25424http://dx.doi.org/10.1007/s11126-014-9290-xengSpringer ScienceSchizophreniaAtypical antipsychoticQuality of lifeQuality of Life in Patients with Schizophrenia: The Impact of Socio-economic Factors and Adverse Effects of Atypical Antipsychotics Drugsinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleThis cross-sectional study compared the effects of treatment with atypical antipsychotic drugs on quality of life (QoL) and side effects in 218 patients with schizophrenia attending the ambulatory services of psychiatric in Rio Grande do Norte, Brazil. Socio-economic variables were compared. The five-dimension EuroQoL (EQ-5D) was used to evaluate QoL, and side effects were assessed using the Udvalg for Kliniske Undersøgelser (UKU) Side Effect Rating Scale and the Simpson–Angus Scale. Data were analysed using the χ 2 test and Student’s t test, with a significance level of 5 %. Average monthly household incomes in the medication groups were 1.1–2.1 minimum wages ($339–$678). UKU Scale scores showed significant differences in side effects, mainly, clozapine, quetiapine and ziprasidone (p < 0.05). EQ-5D scores showed that all drugs except olanzapine significantly impacted mobility (p < 0.05), and proportions of individuals reporting problems in other dimensions were high: 63.6 % of clozapine users reported mobility problems, 63.7 and 56.3 % of clozapine and ziprasidone users, respectively, had difficulties with usual activities, 68.8 and 54.5 % of ziprasidone and clozapine users, respectively, experienced pain and/or discomfort, and 72.8 % of clozapine users reported anxiety and/or depression. Psychiatric, neurological, and autonomous adverse effects, as well as other side effects, were prevalent in users of atypical antipsychotic drugs, especially clozapine and ziprasidone. Olanzapine had the least side effects. QoL was impacted by side effects and economic conditions in all groups. Thus, the effects of these antipsychotic agents appear to have been masked by aggravating social and economic situations.info:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRNinstname:Universidade Federal do Rio Grande do Norte (UFRN)instacron:UFRNTEXTQuality of Life in Patients with Schizophrenia_2014.pdf.txtQuality of Life in Patients with Schizophrenia_2014.pdf.txtExtracted texttext/plain29956https://repositorio.ufrn.br/bitstream/123456789/25424/3/Quality%20of%20Life%20in%20Patients%20with%20Schizophrenia_2014.pdf.txt24e28512af25bf0421bb47bed8fc851eMD53THUMBNAILQuality of Life in Patients with Schizophrenia_2014.pdf.jpgQuality of Life in Patients with Schizophrenia_2014.pdf.jpgIM Thumbnailimage/jpeg5874https://repositorio.ufrn.br/bitstream/123456789/25424/4/Quality%20of%20Life%20in%20Patients%20with%20Schizophrenia_2014.pdf.jpg73e793f99b0b3bdce73901f4133820c3MD54ORIGINALQualityLifePatients_Araujo_2014.pdfQualityLifePatients_Araujo_2014.pdfapplication/pdf322917https://repositorio.ufrn.br/bitstream/123456789/25424/1/QualityLifePatients_Araujo_2014.pdf4156f54b8b8c9286671f19d8c6341e1cMD51LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://repositorio.ufrn.br/bitstream/123456789/25424/2/license.txt8a4605be74aa9ea9d79846c1fba20a33MD52123456789/254242021-11-11 16:28:29.793oai:https://repositorio.ufrn.br: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Repositório de PublicaçõesPUBhttp://repositorio.ufrn.br/oai/opendoar:2021-11-11T19:28:29Repositório Institucional da UFRN - Universidade Federal do Rio Grande do Norte (UFRN)false |
dc.title.pt_BR.fl_str_mv |
Quality of Life in Patients with Schizophrenia: The Impact of Socio-economic Factors and Adverse Effects of Atypical Antipsychotics Drugs |
title |
Quality of Life in Patients with Schizophrenia: The Impact of Socio-economic Factors and Adverse Effects of Atypical Antipsychotics Drugs |
spellingShingle |
Quality of Life in Patients with Schizophrenia: The Impact of Socio-economic Factors and Adverse Effects of Atypical Antipsychotics Drugs Araújo, Aurigena Antunes de Schizophrenia Atypical antipsychotic Quality of life |
title_short |
Quality of Life in Patients with Schizophrenia: The Impact of Socio-economic Factors and Adverse Effects of Atypical Antipsychotics Drugs |
title_full |
Quality of Life in Patients with Schizophrenia: The Impact of Socio-economic Factors and Adverse Effects of Atypical Antipsychotics Drugs |
title_fullStr |
Quality of Life in Patients with Schizophrenia: The Impact of Socio-economic Factors and Adverse Effects of Atypical Antipsychotics Drugs |
title_full_unstemmed |
Quality of Life in Patients with Schizophrenia: The Impact of Socio-economic Factors and Adverse Effects of Atypical Antipsychotics Drugs |
title_sort |
Quality of Life in Patients with Schizophrenia: The Impact of Socio-economic Factors and Adverse Effects of Atypical Antipsychotics Drugs |
author |
Araújo, Aurigena Antunes de |
author_facet |
Araújo, Aurigena Antunes de Dantas, Diego de Araújo Nascimento, Gemma Galgani do Ribeiro, Susana Barbosa Chaves, Katarina Melo Silva, Vanessa de Lima Araújo Jr., Raimundo Fernandes de Souza, Dyego Leandro Bezerra de Medeiros, Caroline Addison Carvalho Xavier de |
author_role |
author |
author2 |
Dantas, Diego de Araújo Nascimento, Gemma Galgani do Ribeiro, Susana Barbosa Chaves, Katarina Melo Silva, Vanessa de Lima Araújo Jr., Raimundo Fernandes de Souza, Dyego Leandro Bezerra de Medeiros, Caroline Addison Carvalho Xavier de |
author2_role |
author author author author author author author author |
dc.contributor.author.fl_str_mv |
Araújo, Aurigena Antunes de Dantas, Diego de Araújo Nascimento, Gemma Galgani do Ribeiro, Susana Barbosa Chaves, Katarina Melo Silva, Vanessa de Lima Araújo Jr., Raimundo Fernandes de Souza, Dyego Leandro Bezerra de Medeiros, Caroline Addison Carvalho Xavier de |
dc.subject.por.fl_str_mv |
Schizophrenia Atypical antipsychotic Quality of life |
topic |
Schizophrenia Atypical antipsychotic Quality of life |
description |
This cross-sectional study compared the effects of treatment with atypical antipsychotic drugs on quality of life (QoL) and side effects in 218 patients with schizophrenia attending the ambulatory services of psychiatric in Rio Grande do Norte, Brazil. Socio-economic variables were compared. The five-dimension EuroQoL (EQ-5D) was used to evaluate QoL, and side effects were assessed using the Udvalg for Kliniske Undersøgelser (UKU) Side Effect Rating Scale and the Simpson–Angus Scale. Data were analysed using the χ 2 test and Student’s t test, with a significance level of 5 %. Average monthly household incomes in the medication groups were 1.1–2.1 minimum wages ($339–$678). UKU Scale scores showed significant differences in side effects, mainly, clozapine, quetiapine and ziprasidone (p < 0.05). EQ-5D scores showed that all drugs except olanzapine significantly impacted mobility (p < 0.05), and proportions of individuals reporting problems in other dimensions were high: 63.6 % of clozapine users reported mobility problems, 63.7 and 56.3 % of clozapine and ziprasidone users, respectively, had difficulties with usual activities, 68.8 and 54.5 % of ziprasidone and clozapine users, respectively, experienced pain and/or discomfort, and 72.8 % of clozapine users reported anxiety and/or depression. Psychiatric, neurological, and autonomous adverse effects, as well as other side effects, were prevalent in users of atypical antipsychotic drugs, especially clozapine and ziprasidone. Olanzapine had the least side effects. QoL was impacted by side effects and economic conditions in all groups. Thus, the effects of these antipsychotic agents appear to have been masked by aggravating social and economic situations. |
publishDate |
2014 |
dc.date.issued.fl_str_mv |
2014-05-01 |
dc.date.accessioned.fl_str_mv |
2018-06-16T12:05:33Z |
dc.date.available.fl_str_mv |
2018-06-16T12:05:33Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
ARAÚJO, Aurigena Antunes de et al. Quality of Life in Patients with Schizophrenia: The Impact of Socio-economic Factors and Adverse Effects of Atypical Antipsychotics Drugs. Psychiatric Quarterly, p. 357-67, 2014. Disponível em: <https://link.springer.com/article/10.1007%2Fs11126-014-9290-x>. Acesso em: 19 mar. 2018. |
dc.identifier.uri.fl_str_mv |
https://repositorio.ufrn.br/jspui/handle/123456789/25424 |
dc.identifier.issn.none.fl_str_mv |
1573-6709 |
dc.identifier.doi.none.fl_str_mv |
http://dx.doi.org/10.1007/s11126-014-9290-x |
identifier_str_mv |
ARAÚJO, Aurigena Antunes de et al. Quality of Life in Patients with Schizophrenia: The Impact of Socio-economic Factors and Adverse Effects of Atypical Antipsychotics Drugs. Psychiatric Quarterly, p. 357-67, 2014. Disponível em: <https://link.springer.com/article/10.1007%2Fs11126-014-9290-x>. Acesso em: 19 mar. 2018. 1573-6709 |
url |
https://repositorio.ufrn.br/jspui/handle/123456789/25424 http://dx.doi.org/10.1007/s11126-014-9290-x |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Springer Science |
publisher.none.fl_str_mv |
Springer Science |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRN instname:Universidade Federal do Rio Grande do Norte (UFRN) instacron:UFRN |
instname_str |
Universidade Federal do Rio Grande do Norte (UFRN) |
instacron_str |
UFRN |
institution |
UFRN |
reponame_str |
Repositório Institucional da UFRN |
collection |
Repositório Institucional da UFRN |
bitstream.url.fl_str_mv |
https://repositorio.ufrn.br/bitstream/123456789/25424/3/Quality%20of%20Life%20in%20Patients%20with%20Schizophrenia_2014.pdf.txt https://repositorio.ufrn.br/bitstream/123456789/25424/4/Quality%20of%20Life%20in%20Patients%20with%20Schizophrenia_2014.pdf.jpg https://repositorio.ufrn.br/bitstream/123456789/25424/1/QualityLifePatients_Araujo_2014.pdf https://repositorio.ufrn.br/bitstream/123456789/25424/2/license.txt |
bitstream.checksum.fl_str_mv |
24e28512af25bf0421bb47bed8fc851e 73e793f99b0b3bdce73901f4133820c3 4156f54b8b8c9286671f19d8c6341e1c 8a4605be74aa9ea9d79846c1fba20a33 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRN - Universidade Federal do Rio Grande do Norte (UFRN) |
repository.mail.fl_str_mv |
|
_version_ |
1802117885900881920 |